Company Overview and News
Wall Street lost one of its best and brightest yesterday, when Rich Yamarone — known to his friends and colleagues as “Yammy”– passed away. He was 55.
Good morning, ladies and gentlemen. Welcome to the RBC 2017 Fourth Quarter Results Conference Call. I would now like to turn the meeting over to Mr. Dave Mun, SVP and Head of Investor Relations. Please go ahead, Mr. Mun.
New York: Venture capital firm Sequoia Capital is looking to increase its stake in app-based cab aggregator Uber by aiming to buy shares from employees and other shareholders when the tender offer launches, likely on Wednesday.
Former Goldman Sachs Equity Analyst and Venture Capital Veteran Brings Additional Crypto and Blockchain Expertise to SNAP Leadership
Stocks were indicated higher on Tuesday after a mixed session on Monday. The markets remain right at all-time highs, and the one trend that has won time after time is that investors have been rewarded every time they buy pullbacks. Those same investors are continuing to look for new investing and trading ideas to generate gains and income ahead.
Wall Street and investors can certainly be fickle friends when it comes to companies and where their money goes. Huge blue chip leaders can often turn into disasters when the fundamentals change, and often those fundamentals change because upper management doesn’t have the vision to change with the times. When bad times come, it sometimes takes a ton of money and, most importantly, courage to step up to the plate and buy.
CAMP HILL, PA--(Marketwired - Nov 28, 2017) - Harsco Corporation (NYSE: HSC) (the "Company") today announced that it is seeking to amend its existing senior secured credit facilities in order to, among other things, reduce the interest rate applicable to the $546 million of term loans outstanding thereunder.
My path to a career as a financial advisor was anything but direct. In college, I managed a game room, hung posters, served beer and checked IDs in the school cafeteria.
Bank of America (BAC) looks to continue higher as its operations improve alongside an attractive valuation multiple. BAC is emerging from a long-term bottoming formation, with upside momentum on its side. BAC is positioned to benefit from an interest rates rise and an improving U.S. economy. Its valuation multiple also is lower than its peers, signaling it could outperform in coming years.
NEW YORK (Reuters) - UBS Group AG’s Wealth Management Americas said on Monday it was quitting a 13-year-old recruiting agreement that ended the practice of suing brokers who quit for jobs at competing firms, following a similar move by rival Morgan Stanley last month.
UBS Group AG's Wealth Management Americas said on Monday it was quitting a 13-year-old recruiting agreement that ended the practice of suing brokers who quit for jobs at competing firms, following a similar move by rival Morgan Stanley last month.
NEW YORK, Nov 27 (Reuters) - UBS Group AG’s Wealth Management Americas said on Monday it was quitting a 13-year-old recruiting agreement that ended the practice of suing brokers who quit for jobs at competing firms, following a similar move by rival Morgan Stanley last month.
The main biotech indices posted small gains in the holiday shortened trading week just before Thanksgiving.
West Texas Intermediate crude closed the day on Friday at $58.97 a barrel, which was the highest price in two years. Despite the dramatic 100% plus move off the lows posted in January of 2016, there is still a large swath of portfolio managers and analysts on Wall Street that remain either neutral or actually underweight the sector. With the potential for an OPEC continuation of the current production costs that are in place this week, it makes sense to look at adding some of the top stocks now.
Stocks were directionless on Monday, with most Americans slowly trickling back into the office after an extended Thanksgiving break. Still, the major U.S. indexes remain close to all-time highs and the trend that has won over and over is for investors to buy every pullback. Investors continue to look for new investing and trading ideas to generate gains and income ahead.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
as of ET